X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial
Synopsis
The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.
X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.
The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said. The strategic restructuring is aimed at aligning resources to complete the late-stage trial in patients with moderate and severe chronic neutropenia, it added.
Shares of the company rose 2% in the pre-market session at the time of writing.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.